A Phase I, randomized, open-label, two-sequence, two-period crossover study to evaluate the effect of food on the pharmacokinetics of D-1553 tablets in healthy subjects
Latest Information Update: 21 Nov 2024
Price :
$35 *
At a glance
- Drugs Garsorasib (Primary)
- Indications Colorectal cancer; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- 19 Nov 2024 New trial record